Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

Kim A. Margolin, Frederick R. Aronson, Mario Sznol, Michael B. Atkins, Nicolae Ciobanu, Richard I. Fisher, Geoffrey R. Weiss, James H. Doroshow, Michael H. Bar, Michael J. Hawkins, James W. Mier, Elisabeth Paietta, Ellen P. Gaynor, David H. Boldt

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

Original languageEnglish (US)
Pages (from-to)214-220
Number of pages7
JournalJournal of Immunotherapy
Volume10
Issue number3
DOIs
StatePublished - Jun 1991

    Fingerprint

Keywords

  • Hodgkin’s disease
  • Interleukin-2
  • Lymphokine-activated killer cells
  • Non-Hodgkin’s lymphoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Margolin, K. A., Aronson, F. R., Sznol, M., Atkins, M. B., Ciobanu, N., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Bar, M. H., Hawkins, M. J., Mier, J. W., Paietta, E., Gaynor, E. P., & Boldt, D. H. (1991). Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma. Journal of Immunotherapy, 10(3), 214-220. https://doi.org/10.1097/00002371-199106000-00008